

02-18-00

H

Please type a plus (+) sign in inside this box → **18**

UTILITY PATENT APPLICATION TRANSMITTAL <i>(Only for new non-provisional applications under 37 CFR 1.53(b))</i>		Attorney Docket No. PH-7076-A
SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION		First Named Inventor or Application Identifier OLSON et al. Express Mail Label No. EL502307526US Express Mailing Date February 17, 2000

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent applications contents.		ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231	
1. <input checked="" type="checkbox"/> Fee (Authority to charge deposit account below.) <i>(Submit an original, and duplicate for fee processing)</i> 2. <input checked="" type="checkbox"/> Specification [Total Pages 259] <i>(preferred arrangement set forth below)</i> - Descriptive title of the invention - Cross Reference to Related Application (if needed) - Statement Regarding Fed sponsored R&D (if needed) - Reference to Microfiche Appendix (if needed) - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claims [Total Claims 32] - Abstract of the Disclosure 3. <input type="checkbox"/> Drawing(s) (35 USC 113 [Total Pages <input type="checkbox"/>] 4. <input checked="" type="checkbox"/> Oath or Declaration [Total Pages 1] a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 14 completed)</i> i. <input type="checkbox"/> DELETION OF INVENTORS Signed Statement below at 15 deleting inventor(s) named in the prior application see 37 CFR 1.63(d)(2) and 1.33(b). 5. <input type="checkbox"/> Incorporation by Reference (useable if Box 4b is The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.		6. <input type="checkbox"/> Microfiche Computer Program (Appendix) 7. Nucleotide and/or Amino Acid Sequence Submissions <i>(if applicable, all necessary)</i> a. <input type="checkbox"/> Computer Readable Copy b. <input type="checkbox"/> Paper Copy (identical to computer copy) c. <input type="checkbox"/> Statement verifying identity of above copies ACCOMPANYING APPLICATION PARTS 8. <input checked="" type="checkbox"/> Power of Attorney 9. <input type="checkbox"/> Information Disclosure Statement (IDS) Cover Letter plus PTO-1449 10. <input checked="" type="checkbox"/> Preliminary Amendment (See Item 16. below) 11. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i> 12. <input type="checkbox"/> Certified Copy priority Document(s) <i>(if foreign priority is claimed)</i> 13. <input type="checkbox"/> Other	
14. If a CONTINUING APPLICATION , check appropriate box and supply the requisite information: <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input checked="" type="checkbox"/> Continuation-in-part (CIP) of prior Application No.: 09/469,939			
15. <input type="checkbox"/> DELETION OF INVENTOR(S) STATEMENT: This application is being filed by less than all the inventors named in the prior application. In accordance with 37 CFR 1.63(d)(2) and 1.33(b), the Assistant Commissioner is requested to delete the number(s) of the following person or persons who are not inventors of the invention being claimed in this application:			
16. <input checked="" type="checkbox"/> Amend the specification by inserting before the first line the sentence: -- This is a continuation-in-part of Application No. 09/469,939 filed December 24, 1999, now pending, which in turn claims the benefit of U. S. Provisional Application No. 60/113,558, filed December 24, 1998.--			
17. <input type="checkbox"/> Cancel in this application original claims ____ of the prior application before calculating the filing. (At least one Original independent claim must be retained for filing purposes.)			
18. <input type="checkbox"/> Priority of foreign Application No. _____ filed on _____ in _____ is claimed under 35 U.S.C. 119.			

jc584 U. S. PTO

09/505700

02/17/00

02/17/00

09/505700


CLAIMS	(1) FOR	(2) NUMBER FIELD	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CRR 1.16(c))	32	12	x \$ (18) =	216.00
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	2		x \$ (78)=	
	MULTIPLE DEPENDENT CLAIM(S) (if applicable)			= \$270 =	\$270.00
			BASIC FEE (37 CFR 1.16(a))		\$760.00
			TOTAL =		\$1,246.00

19. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 04-1928:
- a. ☒ Fees required under 37 CFR 1.16.
- b. ☐ Fees required under 37 CFR 1.17
20. ☐ Other:

21. CORRESPONDENCE ADDRESS

<i>NAME</i>	Scott K. Larsen				
<i>ADDRESS</i>	DuPont Pharmaceuticals Company				
	c/o E. I. duPont de Nemours and Company				
	Legal – Patents				
<i>CITY</i>	1007 Market Street	<i>STATE</i>	Delaware	<i>ZIP CODE</i>	19898
<i>COUNTRY</i>	U.S.A.	<i>TELEPHONE</i>	302-992-2368	<i>FAX</i>	302-892-8536

22. SIGNATURE OF ATTORNEY OR AGENT REQUIRED

22. SIGNATURE OF ATTORNEY OR AGENT REQUIRED		
NAME	Scott K. Larsen	REG. NO.: 38,532
SIGNATURE		
DATE	February 17, 2000	